Elan Risking $2 Billion If Royalty Pharma Walks: Real M&A

Elan Corp. shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.